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One Sentence Summary: Dengue virus NS1 induces innate inflammatory responses via TLR4 
signaling and disrupts endothelial cell layer integrity. 
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Abstract 
Complications arising from dengue virus infection include potentially fatal vascular leak, with severe 
disease being linked with excessive immune cell activation. Understanding the underlying triggers of 
this activation is critical for developing appropriate disease control strategies. We show here that the 
secreted form of the dengue virus non-structural protein NS1 is a pathogen-associated molecular 
pattern (PAMP). Highly purified NS1, devoid of bacterial endotoxin activity, directly activated mouse 
macrophages and human peripheral blood mononuclear cells (PBMCs) via toll-like receptor 4 (TLR4) 
leading to the induction and release of proinflammatory cytokines and chemokines. In an in vitro model 
of vascular leak, treatment with NS1 alone resulted in the disruption of endothelial cell monolayer 
integrity. Both NS1-mediated activation of PBMCs and NS1-induced vascular leak in vitro were 
inhibited by a TLR4 antagonist and by anti-TLR4 antibody treatment.  The importance of TLR4 
activation in vivo was confirmed by the reduction of capillary leak by a TLR4 antagonist in a mouse 
model of dengue virus infection. The results point to NS1 being a viral toxin counterpart of bacterial 
endotoxin. Similar to the role of LPS in septic shock, NS1 may contribute to vascular leak in dengue 
patients with TLR4 antagonists a therapeutic option in dengue disease. 
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Introduction 
Dengue virus infection is an increasing problem in tropical and subtropical areas, and is endemic in 
over a hundred countries (1). With climate change extending the range of the mosquito vector, as well 
as increased travel, more populations will become at risk of dengue infection. There are an estimated 
390 million dengue infections globally per year, 96 million of these being symptomatic with many 
thousands of deaths (1). Despite this global health burden, no vaccine or therapeutic intervention has 
yet been licensed. Dengue infection causes a spectrum of diseases ranging from undifferentiated fever, 
classical dengue fever (DF) to severe and potentially fatal dengue hemorrhagic fever (DHF) and 
dengue shock syndrome (DSS). Severe disease is characterized by the rapid onset of capillary leak 
accompanied by thrombocytopenia and altered haemostasis. While the mechanistic basis of dengue-
mediated capillary leak remains the subject of considerable conjecture, the host immune response 
appears to be an important determinant of disease outcome. In comparison with less severe cases, 
DHF/DSS patients have higher levels of circulating pro-inflammatory cytokines and chemokines, 
referred to as a cytokine storm (2). These vasoactive mediators are thought to play a major role in the 
collapse of vascular integrity (3, 4) with both activated T cells and monocytes being proposed as 
critical in their production (5, 6). Although DHF and DSS can accompany primary infection in infants 
(7), they more frequently occur upon secondary infection in older children and adults with a different 
dengue virus serotype. The anamnestic induction of high levels of cross-reactive, but sub-neutralizing 
antibodies during the acute stage of secondary infection has been hypothesized to contribute to 
antibody-dependent enhancement (ADE) of infection in Fc receptor-bearing cells resulting in both 
higher virus levels and elevated cytokine production (8, 9). ADE in primary infection in infants in the 
absence of a secondary immune response is thought to be due to the presence of maternally-acquired 
antibodies that have declined to sub-neutralizing levels (7).  It has also been proposed that activation in 
secondary infections of cross-reactive, and consequently low affinity memory T-cell responses to the 
primary infecting virus, results in delayed viral clearance (5) and elevation of inflammatory cytokines 
that contribute to the pathology of severe disease (2). However, severe disease in primary infections of 
infants (7) demonstrates that memory T cell responses are not essential for severe pathology. Viral 
strain virulence, host genetics, and nutritional status are all likely additional risk factors in progression 
to severe disease (10).  
 
The dengue virus non-structural protein NS1 is a multi-functional, 48-55 kDa glycoprotein, that is 
initially synthesized as a soluble monomer and becomes membrane-associated following dimerization 
in the lumen of the endoplasmic reticulum (11). The recent crystal structure determination of NS1 has 
revealed exposed hydrophobic domains on the dimeric form that are likely to mediate this membrane-
association (12). Intracellular NS1 participates in early viral RNA replication and is found in virus-
induced vesicular compartments that house the viral replication complexes (13). NS1 is also 
transported to the cell surface, where it either remains associated with the cell membrane, or is secreted 
as a soluble, lipid-associated hexameric species. A small subset of cell-surface expressed NS1 has been 
shown to be membrane-associated via a glycosyl-phosphatidylinositol (GPI)-anchor, which can 
mediate signal transduction on specific antibody engagement, thereby facilitating enhanced production 
of viral progeny (14). Secreted NS1 (sNS1) can be detected in the bloodstream of infected patients 
from the first day of symptoms and circulates at levels in the ng/ml to µg/ml range during the acute 
phase of infection (15, 16).  This circulating viral biomarker has now become a target for diagnosis of 
early acute infection, (17, 18) and levels correlate with viremia and disease severity in secondary 
dengue infection (16, 19). NS1 is thought by some to play a number of roles in the pathology of 
infection, including both stimulation and inhibition of complement pathways, and damage to platelets 
and endothelial cells by cross-reactive anti-NS1 antibodies (11, 19, 20). 
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In this study we examined whether sNS1 directly stimulates innate immune responses. Recognition of 
pathogen-associated molecular patterns (PAMPs) by receptors such as TLRs on innate immune cells 
can mediate induction of cytokines and promote antigen presenting cell function. For example, 
components of the Gram-negative bacterial outer membrane, LPS and lipoproteins, are recognized by 
TLR4 and TLR2 respectively (21). Recognition of viral nucleic acids by endosomal TLRs 3, 7, and 9 
as well as other cytosolic receptors provides a versatile means of response to a wide range of viruses. 
Several viral proteins are also reported to be direct TLR agonists; the measles virus hemagglutinin (H) 
protein, hepatitis C virus core and NS3 proteins, and NSP4 of rotavirus all signal through TLR2 (22-
24) while the respiratory syncytial virus fusion (F) protein (25) Ebola virus glycoprotein (26) and 
mouse mammary tumour virus envelope protein (27) were reported to induce inflammatory cytokines 
via TLR4 activation. Specific TLR activation by viral proteins seems counter-intuitive. It would be 
reasonable to expect that RNA viruses would rapidly evolve to evade TLR detection, much as viruses 
have evolved numerous strategies for avoiding the inhibitory effects of interferon. However, in some 
cases TLR activation may induce a cellular state that favours viral replication and/or transmission. 
Innate immune responses are not always protective, but may contribute to pathology, particularly when 
uncontrolled.  
 
Here we show that dengue virus NS1 elicits inflammatory cytokine production and endothelial cell 
monolayer leak via TLR4, and TLR4 antagonism decreases vascular leak in a mouse model of 
infection. By analogy to LPS-induced shock in sepsis, NS1-induced cytokines as well as direct effects 
on endothelial cell function may play an important role in the vascular leak and shock that is the 
hallmark of DHF/DSS. 
 
Results 
NS1 activates human and mouse immune cells 
We hypothesized that circulating NS1 directly activates innate immune cells. Recombinant, hexameric 
sNS1 was isolated from media harvests of S2 cells stably expressing dengue virus 2 (DENV2) NS1 by 
immunoaffinity chromatography, and its purity assessed by SDS-PAGE and size exclusion 
chromatography (Fig.  S1). Purified recombinant NS1 was shown to be LPS-free by the Limulus 
amebocyte lysate (LAL) assay; readings for NS1 at 40 µg /ml indicated <0.1 EU/ml or <10 pg LPS/ml 
equivalent. Throughout this study LPS was used as a positive control for TLR4 activation. Purified 
sNS1 and LPS both strongly induced the secretion of IL-6 from peripheral blood mononuclear cells 
(PBMCs) (Fig. 1A), suggesting NS1 behaves as a PAMP. NS1 immunodepletion prevented IL-6 
induction, whereas a control antibody neither depleted NS1 nor abrogated activity (Fig. 1A). An NF-
κB-responsive mouse macrophage reporter cell line was also activated by NS1 (Fig. S2) 
 
LPS-inhibitory Polymyxin B does not affect NS1 stimulatory activity 
In defining novel PAMPs, the elimination of bacterial contaminants is critical. The immunodepletion 
results above demonstrate that either NS1 or a factor bound to NS1 activates both mouse and human 
cells. Since hexameric NS1 is a lipid-binding protein (28), it is conceivable that the insect (S2) cell-
derived NS1 could have bound trace amounts of bacterial lipids such as LPS during the purification 
process. Although the LAL assay did not detect any endotoxin, to further allay concerns about 
contaminating LPS, we examined the induction of IL-6 in human PBMCs using NS1 pretreated with 
the LPS-binding antibiotic polymyxin B. Polymyxin B inhibited the response to concentrations of LPS 
≤ 10 ng/ml, whilst the NS1-mediated response was unaffected (Fig. 1B). Polymyxin B was also able to 
inhibit low concentrations of LPS spiked into NS1 samples (Fig. S3), demonstrating that NS1 was 
unlikely to sequester contaminating endotoxin making it unavailable for polymyxin B inhibition. To 
facilitate characterization of the mechanism, we moved to mouse cells, and measured down-modulation 
of the receptor for the macrophage growth factor, colony stimulating factor-1 (CSF1) in bone marrow-
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derived macrophages (BMMs). Cell surface CSF1 receptor (CSF1R) is increased on CSF1-starved 
BMMs and rapidly lost in response to TLR agonists including LPS, making a convenient and sensitive 
assay for TLR agonists (29). Both LPS and NS1 down-modulated surface CSF1R (Fig. S4). Only the 
LPS response was sensitive to polymyxin B (Fig. 1C), and thus LPS contamination is not a likely 
explanation for the NS1 response of mouse or human cells. 
 
NS1 activity is not due to a co-purifying contaminant 
The possibility remained that the active component of the NS1 preparation was a NS1-binding 
contaminant distinct from LPS. To eliminate any concerns about introduction of bacterial contaminants 
during the purification process, we assessed the activity of NS1 expressed by mammalian cells, without 
purification. Medium, transfection reagent (PEI), plasmids and transient transfection harvests were all 
tested by the LAL assay and shown to be LPS-free (<0.1 EU/ml or <10 pg LPS/ml equivalent). As 
expected, the S2-derived NS1 caused loss of CSF1R, and this was prevented by NS1 immunodepletion 
(Fig. 2A). Medium derived from NS1 expression vector-transfected CHO cells also reproducibly 
reduced surface CSF1R levels, whilst immunodepletion of NS1 prevented this activity (Fig. 2B). Media 
from untransfected or empty vector-transfected CHO cells had no effect on CSF1R levels. CHO cell-
derived NS1 also induced IL-6 from human PBMCs, and this activity could be specifically removed by 
immunodepletion of NS1 (Fig. 2C). Taken together, the data show that the NS1 lipoprotein, rather than 
any contaminant in the NS1 preparations has direct immunostimulatory activity.  
 
All flaviviruses encode a homologous NS1 protein, with remarkable structural similarity observed 
between DENV NS1 and West Nile virus (WNV) NS1 (12). Therefore it was of interest to determine 
whether other flavivirus NS1 species were also stimulatory. We transiently expressed WNV (NY99) 
and yellow fever virus (YFV) NS1 in CHO cells and found that both induced detectable secretion of 
IL-6 from cultured PBMCs (Fig. S5). This suggests a possible common strategy amongst the 
flaviviruses of inducing innate immune activation. However, the accompanying paper (30) found that 
West Nile virus NS1 did not disrupt endothelial cell monolayer integrity, consistent with lack of 
peripheral vascular leak in West Nile virus disease. Ultimately, the contribution of different species of 
NS1 to TLR4-mediated responses in flavivirus infections will depend on their levels of release, 
distribution in the body, and individual potencies, which remain to be fully determined. Of interest, a 
short peptide motif in the N-terminal region of NS1 that is divergent between WNV and DENV targets 
the majority of WNV NS1 to the cell surface whilst DENV NS1 is predominantly secreted (31).  
 
NS1 protein induces pro-inflammatory cytokines in mouse macrophages and human PBMCs 
Pro-inflammatory cytokines such as TNF-α, IFN-γ, IL-6, IL-1β and MIF, and chemokines such as IL-8, 
IP-10 and MCP-1 are induced during the acute phase of dengue infection with levels correlating with 
disease severity (3, 7, 32, 33). NS1 induced a dose-dependent increase in the levels of mRNA for TNF-
α, IL-6, IFN-β, IL-1β, and IL-12 in mouse BMMs, although this had not reached a maximal response at 
40 µg/ml NS1 (Fig. 3A and Fig. S6A). NS1 induced these genes in a similar time course to LPS (Fig. 
3B, Fig. S6B). Whereas the response of mouse BMMs to relevant concentrations of NS1 was much 
lower than the response to LPS, both agents produced strong induction of cytokine mRNAs in human 
PBMCs, with NS1 being a particularly potent inducer of IL-6 and IL-1β gene expression (Fig. 3C, Fig. 
S6C). This suggests a measure of species specificity in the recognition of the NS1 protein.  IL-12 was 
induced at a later time than other genes, and IP-10 and MCP-1 showed modest induction by both 
agents (Fig. S6C). 
 
NS1 is recognized via TLR4 
TLRs are the most likely candidates for cell surface receptors that recognize extracellular NS1 and 
mediate activation of NF-κB and cytokine induction. TLR2 and 4 have been observed to respond to 
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several viral proteins (22-27). We therefore examined down-modulation of CSF1R on BMMs from 
mice lacking either individual TLRs, or TLR signaling adapters MyD88 and TRIF. The responses to 
both LPS and NS1 were lost in Tlr4-/- and MyD88-/-/Trif-/- macrophages, but were intact in Tlr2-/- cells. 
Pam3CSK4 was used as a control stimulus for TLR2 (Fig. 4A and B). Tlr4-/- BMM also failed to 
respond to NS1 with increased TNF-α, IL-1β or other cytokine mRNAs (Fig. 4C-D and Fig. S7A), but 
these responses were intact in Tlr2-/- cells (Fig. 4E-F and Fig. S6B). To confirm that human TLR4 
recognizes NS1, IL-8 mRNA was measured in HEK293 cells ectopically expressing TLR4/MD2 or 
TLR2, stimulated with NS1, LPS or Pam3CSK4. A response to NS1 and LPS was seen in cells 
expressing TLR4/MD2 (Fig. 4G) but not TLR2 (Fig. 4H), consistent with the results from BMMs of 
gene-targeted mice.  
 
NS1 and TLR4 co-localize on the cell surface. 
To determine whether cell surface TLR4 and NS1 co-localize, adherent PBMCs were exposed to NS1 
then washed and fixed, and stained with antibodies for confocal microscopy. Although co-localization 
was not complete, a large number of foci displayed overlapping signal for TLR4 and NS1 on the 
surface of cells (Fig. 5A, controls in Fig. S8). Z stack analysis showed clear association in isolated 
regions of the membrane (Fig. 5A and Movie S1; z stack video). Amongst PBMCs, monocytes are the 
most abundant cells with readily detectable TLR4 expression, with lymphocytes expressing very little 
TLR4 mRNA (34). The adherent PBMCs were a mixture of cell types, and interestingly, the smaller 
cells without observable surface TLR4 were also devoid of detectable NS1 binding (Fig 5B).  
 
Activation of PBMC by NS1 can be blocked by a TLR4 antagonist 
To demonstrate the involvement of TLR4 in human PBMC responses to NS1, we took advantage of a 
naturally occurring TLR4 antagonist. The pattern of lipid A acylation of Rhodobacter sphaeroides LPS 
(LPS-RS) renders it non-stimulatory, and inhibitory to active LPS by competitive binding to the 
TLR4/MD-2 complex (35, 36). Pre-treatment of PBMCs with LPS-RS completely inhibited induction 
of IL-6 and IL-8 by LPS and NS1 but not Pam3CSK4 (Fig. 6A and Fig. S9). A TLR4 blocking antibody 
also reduced the NS1 response. More complete inhibition of NS1 than LPS activity was seen, which 
may reflect a greater ability of the antibody to sterically block the larger NS1 macromolecule (Fig. 6B 
and Fig. S9). 
 
NS1 disrupts endothelial cell monolayers and is inhibited by a TLR4 antagonist  
Vascular leakage leading to shock is one of the hallmarks of severe dengue disease. NS1 could 
contribute to vascular leak through direct activation of endothelial cells, which can also express TLR4 
(37). We analyzed the effect of exposure to NS1 or LPS on the integrity of human microvasculature 
endothelial cell (HMEC-1) monolayers grown in transwell cultures, by measurement of trans-
endothelial electrical resistance (TEER). Compared to the mock-treated monolayers, leak was observed 
by the first hour for NS1-treated cells and 5 hours for LPS-treated cells with both peaking between 9 
and 11 hours (Fig. 6C). Pre-treatment with LPS-RS completely blocked leak, and an anti-TLR4 
antibody inhibited leak induced by both NS1 and LPS (Fig. 6C). This implies that in addition to 
mediating cytokine induction from monocytes/macrophages, NS1 recognition by TLR4 on endothelial 
cells directly contributes to vascular leak. 
 
A TLR4 antagonist protects against vascular leak in a mouse model of infection 
In order to extend these in vitro findings into an in vivo model, we examined the effects of LPS-RS 
treatment on capillary leak induced in DENV2 (strain D220) (38) infected AG129 mice.  The virus 
dose was non-lethal, but infected mice examined 4 days post-infection exhibited significant vascular 
leak in several tissues as measured by tissue content of intra-venous delivered Evans Blue dye (Fig. 
6D-E). Daily intra-peritoneal injection of LPS-RS (50 µg) greatly reduced capillary leak induced by 
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DENV infection (Fig. 6D-E), indicating that inhibition of NS1-mediated TLR4 activation may offer a 
new disease intervention strategy. 
 
Discussion 
In this study we showed that the hexameric, secreted form of dengue virus NS1 directly activated 
mouse macrophages and human PBMCs via TLR4 with the consequent release of pro-inflammatory 
cytokines. Thus, NS1 may contribute to triggering the cytokine storm proposed as being responsible for 
the vascular leak and shock in severe dengue disease (3). In addition, NS1 directly impaired endothelial 
cell monolayer integrity in an in vitro model of leak, and a TLR4 antagonist inhibited vascular leak in 
vivo. These findings provide a mechanistic framework for the in vivo activity of sNS1 reported in the 
accompanying paper (30), and together provide a new paradigm for NS1 in dengue disease 
pathogenesis. 
 
TLR4 is expressed on several cell types including monocytes, macrophages and endothelial cells. 
TLR4 and co-receptor MD-2 together mediate responses to bacterial LPS, with the crystal structure of 
the complex revealing that the predominant interaction involves the acyl chains of the central lipid A 
core of LPS being buried in a hydrophobic pocket in MD-2 (39). Antagonists of human TLR4 
signaling, such as LPS-RS, and its synthetic counterpart eritoran, bind within the MD-2 hydrophobic 
pocket but lack a critical acyl chain required for TLR4-MD-2 complex dimerisation and signaling (40). 
We found that LPS-RS was also a potent antagonist of NS1-mediated cytokine induction and vascular 
leak, suggesting that NS1 also interacts with MD-2.  
 
In addition to LPS, TLR4 is reported to mediate responses to many other structurally and chemically 
diverse ligands of bacterial, viral, and host origin. It has been proposed that rather than being true 
TLR4 ligands, many of these actually either bind and present LPS to cells, or sensitize cells to respond 
to LPS (41). We used several approaches to confirm that NS1 lipoprotein alone mediates the observed 
TLR4 activation, although the relative contributions of NS1 protein and its associated lipid moieties 
remain to be established. There is precedent for direct TLR4 recognition of a viral protein, in the 
reported response to RSV F protein (25). RSV F protein responses, like NS1, are inhibited by LPS-RS, 
with the hydrophobic N terminal region of the F protein shown to be responsible for interaction with 
the TLR4-MD-2 complex (42). The crystal structure of NS1 dimer and hexamer assemblies has 
revealed exposed hydrophobic domains (12), which are candidate regions for TLR4 interaction. 
 
Increased vascular permeability is the primary manifestation of severe dengue and so the mechanism of 
endothelial cell responses to dengue infection is of great interest. In dengue patients, levels of TNF-α, 
IL-1β, IL-6, IFN-γ, IL-8 and MCP-1 all correlate with disease severity (3, 32, 33). NS1 was shown in 
this study to directly induce a similar array of pro-inflammatory cytokine and chemokine mRNAs, 
many of which are implicated in the perturbation of endothelial cell barrier function. For example, IL-
1β in combination with TNF-α and IFN-γ affects the barrier function of endothelial cells (43) while IL-
8 and MCP-1 are both reported to alter endothelial tight junctions (32, 44). In the context of dengue 
infection, TNF-α has been suggested as a mediator of dengue-associated hemorrhage via induction of 
endothelial cell apoptosis (45). In addition to its role in induction of cytokines, NS1 may also have a 
direct effect on endothelial cells. The loss of in vitro endothelial monolayer integrity observed here 
after only 1-2 hours of exposure to NS1 (Fig. 6C) is most likely a direct effect of NS1-induced 
signaling pathways on cellular tight junctions. LPS has been shown to directly induce endothelial leak 
via TLR4, with involvement of calcium influx (46) and tyrosine kinase pathways (47). A similar role 
for NS1 is supported by the inhibition of NS1 induced leak by LPS-RS in vitro (Fig. 6C) and is 
suggested by our finding in a mouse model that vascular leak associated with DENV infection can be 
substantially blocked by pre-treatment with LPS-RS (Fig. 6D-E). 
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The role of both virus and host cell factors in the kinetics and severity of dengue disease progression, 
particularly in secondary infections, is complex (3-5, 9), and secreted NS1 is likely to be only one of a 
number of risk factors determining disease severity. NS1 itself may have multiple effects in pathology 
(11), via mechanisms including direct engagement with complement components (19) and the 
induction of anti-NS1 antibodies which cross-react with platelets (20). However, the decrease in 
vascular leak in a mouse model of infection seen here, upon treatment with a TLR4 antagonist, 
suggests that NS1 activation of TLR4 has a causal role in pathology. If so, it might be anticipated that 
vascular permeability and severe pathology would coincide with peak levels of NS1. However the 
observation in the accompanying paper (30) that maximal morbidity was not observed until 3 days after 
administration of NS1 to mice suggests a more complex scenario. In human disease, severe 
complications occur at a time when both viremia (16) and detectable circulating NS1 are declining, 
although these follow different kinetics, with NS1 levels dropping more than a day later than virus (16). 
This apparent clearance of NS1 from circulation may reflect sequestration of NS1 within tissues, not 
necessarily the cessation of NS1 expression and/or its related effects. Indeed, in vitro work has shown 
that NS1 bound avidly to endothelial cells within tissue sections (48). Hence the concentrations of NS1 
at its site of action in vivo may not be reflected in detectable circulating levels. In summary, the 
dynamics of NS1 are currently difficult to assess, and the effects of NS1 may not be immediate.  
 
A role for TLR4 in dengue pathology offers a route to therapeutic intervention with the possible re-
purposing of existing sepsis drug candidates. Although the LPS antagonist eritoran was not successful 
in Phase III clinical trials for sepsis (49), treatment was only initiated after onset of organ dysfunction.  
It remains to be seen whether there is a therapeutic window in which the blocking of NS1 activity early 
during acute dengue virus infection with compounds such as eritoran can ameliorate subsequent 
progression to pathology. Given that the Ebola glycoprotein has also been reported to activate TLR4 
(26) and that there is a role for TLR4 in the pathology induced by infection with another flavivirus, 
Japanese encephalitis virus (JEV) (50) there may be a broader scope for TLR4 antagonists in treatment 
of viral disease. NS1 has also been considered a target for vaccine development (51), and immunization 
with NS1 has been shown to protect mice from lethal dengue virus challenge (52, 53). Our study and 
that of the accompanying paper (30) suggest that such vaccines could have additional efficacy by 
clearing NS1 early during acute infection and thereby reduce NS1-induced pathology. Overall, the 
parallels between NS1 and LPS are compelling; LPS in bacterial sepsis contributes to a cytokine storm, 
vascular permeability and septic shock, and NS1 may generate an analogous viral toxic shock in 
dengue virus infected patients. 
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Materials and Methods 
Additional detailed materials and methods can be found in supplementary material online. 
 
Experimental Design 
 
The aim of this study was to investigate a direct role for the dengue virus secreted glycoprotein, NS1 in 
disease pathogenesis. Using in vitro models we assessed the ability of recombinant NS1 to activate 
human PBMCs and induce permeability in a model vascular cell layer. Cellular activation was assessed 
through the measurement of both mRNA and expressed protein. Using cells from knockout mice we 
attributed this activity to a TLR4-dependent pathway. We sought to exclude the possibility of LPS 
contamination by utilizing polymyxin B LPS-sequestration, sensitive LPS detection, and through using 
NS1 derived from an alternate source and in the absence of purification. We investigated the ability of 
TLR4 antagonists to block NS1-induced cellular activation and leak using in vitro models and then 
translated these findings to an in vivo dengue disease model. AG129 mice (type I and II IFN receptor 
deficient) were chosen as they exhibit typical signs of severe dengue disease. Vascular leak was 
assessed using Evans blue quantification from tissue samples. Group sizes were selected on the basis of 
our experience with these systems. Mice were age- and sex-matched between groups. Investigators 
were not blinded when conducting or evaluating the experiments, and no randomization was necessary. 
No data were excluded from this study. 
 
Materials 
Ultrapure LPS from E.coli 0111:B4 strain, LPS-RS and polymyxin B were obtained from InvivoGen, 
Pam3CSK4 kindly provided by Kelly Smith (Dept. of Pathology, University of Washington, Seattle 
WA, USA) was originally purchased from Roche. The anti-TLR4 antibody (HTA125) was purchased 
from Abcam. 
 
Cell Culture 
BMMs were obtained by differentiation of mouse bone marrow progenitors in the presence of 104 U/ml 
CSF1 for 7 days (29). Use of mice was approved by the University of Queensland Animal Ethics 
Committee. Blood was obtained from healthy volunteers under approval from the University of 
Queensland Medical Research Ethics Committee, and PBMCs were isolated by Ficoll gradient. 
HEK293 cells, stably transfected with hTLR2 or hTLR4/MD-2 were obtained from Doug Golenbock, 
University of Massachusetts. Human microvasculature endothelial cells (HMEC-1) were obtained from 
Philip Hogg, Lowy Cancer Research Centre, University of NSW. 
 
Generation and purification of DENV2 NS1 and transient expression of WNV and YFV NS1 
Recombinant DENV2 NS1 was expressed by stably transfected Drosophila S2 cells. The protein was 
affinity purified from culture medium using a column coupled with the 2A5.1 anti-NS1 monoclonal 
antibody. NS1 proteins from dengue virus, West Nile virus (strain NY99) and yellow fever virus (stain 
17D) were also transiently expressed in Chinese hamster ovary cells (CHO).  Transfection complex 
was washed away after 4 hours. The medium was harvested at day 2 post-transfection and concentrated 
using a 100 kDa cut-off spin column (Millipore). Recombinant NS1 preparations were tested for LPS 
contamination by the Limulus amebocyte lysate assay using the LAL Chromogenic Endotoxin 
Quantitation Kit (Pierce) and shown to be endotoxin free (background readings representing <0.1 
EU/ml or <10 pg endotoxin/ml equivalent were found for purified DENV2 NS1 at 40 µg/ml and for the 
working stocks of transiently expressed and concentrated NS1 preparations).  Immunodepletions of 
NS1 were performed using mouse monoclonal anti-NS1 antibody (1H7 or 2A5) and control anti-E 
antibody (3H5), purified from ascites were bound to protein G Dynabeads (Life Technologies).  
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CSF-1R down-modulation assay 
BMMs were cultured overnight in complete RPMI1640 medium without CSF1. Cells were 
subsequently treated with NS1, LPS, Pam3CSK4 or immunodepleted NS1 for 1 hour in a 
microcentrifuge tube, and then stained for CSF1R and analysed by flow cytometry as described (29).  
 
Analysis of mRNA by quantitative real-time reverse transcriptase PCR (qRT-PCR) 
Mouse BMMs (with CSF1), or human PBMCs were treated with NS1 or TLR ligands for indicated 
times and HEK293 cells and HEK293-TLR cell lines for 3 hours prior to harvest for RNA extraction. 
cDNA was prepared using random hexamer primers and qPCR carried out using gene-specific primers 
(Table S1 and S2) and SYBER©green PCR MasterMix (Life Technologies). Hprt gene expression was 
used as the reference for both mouse and human genes. 
 
Detection of cytokine productions by ELISA 
Human PBMCs were incubated for 24 hours with NS1 or LPS. In some experiments, LPS-RS was pre-
incubated with cells for 30 minutes. The media of treated cells were harvested and centrifuged at 1000g 
for 5 minutes. The levels of IL-6 and IL-8 production were quantified by ELISA (R&D Systems).  
 
Indirect immunofluorescence and confocal microscopy 
PBMCs adherent to coverslips were incubated with NS1 (10 µg/ml) for 45 minutes at 37oC. Cells were 
washed, fixed with 4% paraformaldehyde in PBS, blocked with PBS containing 0.05% non-fat dry 
milk and 0.05% Tween-20, and stained with rabbit anti-NS1 polyclonal antibody and mouse anti-TLR4 
monoclonal antibody (HTA125), followed by goat anti-rabbit Alexa Fluor 488-conjugated and goat 
anti-mouse Alexa Fluor 555-conjugated secondary antibodies (Life Technologies). The cells were 
examined using ZEISS 510 and 710 META microscopy at 100x magnification. The images were 
analyzed using ImageJ version 10.  
 
Trans-endothelial electrical resistance (TEER) measurement of HMEC-1 monolayer integrity 
Transwell polycarbonate membranes (Corning Inc.) were coated with 100 µL fibronectin (Sigma) at 10 
µg/ml for 30 minutes at 37˚C and 5% CO2 and liquid subsequently removed and membranes dried for 
45 minutes at 37°C and 5% CO2. HMEC-1 cells were seeded on transwells and optimal monolayer 
formation was established 4 days post seeding. Prior to agonist stimulation the cells were pre-incubated 
with LPS-RS (100 µg/ml) or anti-TLR4 antibody (20 µg/ml) for 1 hour before the addition of LPS or 
NS1. Endothelial permeability was evaluated over 48 hours by measuring trans-endothelial electrical 
resistance (TEER) using the EVOM2 epithelial voltohmmeter (World Precision Instruments).  
 
Efficacy of LPS-RS in inhibiting dengue virus-induced vascular leak in vivo.  
Mouse experiments were approved by the University of Queensland animal ethics committee. AG129 
mice, which lack receptors for IFN-α/β as well as IFN-γ (54) were bred at the University of 
Queensland. Mouse adapted DENV2 strain D220 (38) was kindly provided by Eva Harris (School of 
Public Health at the University of California, Berkeley). Mice were administered with LPS-RS (50 µg 
per mouse, i.p.) 1 hour prior to infection with DENV (104 PFU per mouse, i.p.) or mock infection. 
LPS-RS or PBS was administered daily (50 µg per mouse, i.p.) for the duration of the experiment. 
Mice were observed every 12 hours for morbidity scoring. Vascular leakage was quantified with Evans 
blue dye as previously described (55). Briefly, 200 µl of 5 mg/ml Evans blue dye was injected i.v. 4 
days post-infection and allowed to circulate for 2 hours before mice were anesthetized and extensively 
perfused with PBS. Tissues were collected in pre-weighed tubes containing 1 ml N,N-
dimethylformamide and incubated at 37oC for 24 hours. Extracted Evans blue was assessed by 
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measuring OD610 in samples, in comparison with a standard curve. Data were expressed as ng Evans 
blue dye/mg tissue weight. 
 
Statistical analysis 
Statistical analyses were performed in Prism 6.0 (GraphPad Software Inc.). Data are shown as means ± 
SD or means ± range. Analytical tests for statistical significance and P values are specified in each 
figure legend. Significance testing of vascular leak levels within mice, expressed as a ratio of Evans 
blue dye to tissue (w/w, normalized), was performed using ordinary one-way ANOVA (Sidak’s 
multiple comparison test). 
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Fig. S2 Dengue NS1 activates a mouse macrophage NF-κB reporter cell line. 
Fig. S3. Polymyxin B can efficiently inhibit LPS in the presence of NS1. 
Fig. S4. NS1 protein causes the loss of surface CSF1R on murine BMMs. 
Fig. S5. Recombinant NS1 from other flaviviruses have immunostimulatory activity.  
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Fig. S9. Inhibition of PBMC production of IL-8 in response to NS1 by anti-TLR4 antibody and TLR4 
antagonist. 
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Figures 
 
Fig. 1. Dengue NS1 activates human and mouse innate immune responses, and is not inhibited by 
LPS-binding antibiotic polymyxin B. (A) NS1 induces IL-6 secretion by human PBMCs. Cells were 
treated for 24 hours with LPS (100 ng/ml), NS1 (40 µg/ml), or an analogous NS1 sample 
immunodepleted with anti-NS1 or anti-E antibody. IL-6 was measured by ELISA. Data shown is mean 
± SD of three donors. The inset immunoblot is of the supernatant fraction following immunodepletion 
using anti-NS1 antibody or isotype-matched control antibody. (B) Polymyxin B does not block NS1-
induced IL-6 in human PBMCs. NS1 and LPS were pre-incubated for 30 minutes with or without 
polymyxin B, then added to PBMCs and incubated for 24 hours.  The final concentration of polymyxin 
B was 25 µg/ml, with varying concentrations of LPS (0.1, 1, 10 ng/ml) and NS1 (5, 10, 20 µg/ml). 
Experiment was run in parallel with (A) and separated for clarity. (Mean ± SD of three donors).  (C) 
Polymyxin B does not block NS1-induced loss of surface CSF1R on BMMs. NS1 and LPS were pre-
incubated for 30 minutes with or without polymyxin B then added to BMMs that had been starved of 
CSF1 overnight. The final concentration of polymyxin B was 25 µg/ml (19.2 µM), with LPS (10-fold 
dilutions from 100 ng/ml, or 10 nM assuming average Mr=10 kDa) and NS1 (2-fold dilutions from 10 
µg/ml, or 33.3 nM). After 1 hour of treatment, CSF1R levels were determined by flow cytometry, with 
the % of cells with high levels of receptor plotted. Data are the mean ± SD from three independent 
experiments. 
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Fig. 2. NS1 from several sources has immunostimulatory activity. (A) NS1 immunodepletion 
prevents the down-modulation of surface CSF1R by S2 cell-expressed NS1. BMMs starved of CSF1 
overnight were treated with either PBS, CSF1 (104 U/ml), LPS (100 ng/ml), NS1 (10 µg/ml), or NS1 
immunodepleted with anti-NS1 antibody or control anti-E antibody. Data are the mean ± SD from three 
independent experiments. (B) Minimally processed CHO cell-expressed NS1 has similar activity to S2 
cell-derived NS1. CHO cells were transfected with either empty expression vector, or a plasmid 
encoding NS1 under the control of the CMV promoter. Culture medium, concentrated with 100 kDa 
cut-off filters, from untransfected cells (control SN), empty vector (pcDNA SN) or NS1 expression 
vector transfected cells (NS1 SN), was applied to CSF1-starved BMMs. The final concentration of 5 
µg/ml NS1 (as quantified by capture-ELISA) represents approximately 4-fold higher levels than 
produced in the CHO cell medium. Cells were also exposed to NS1 SN following immunodepletion 
with anti-NS1 antibody or control anti-E antibody, and to CSF1. Data are the mean ± range from two 
independent experiments. Immunoblot analysis for NS1 confirms immunodepletion. (C) CHO cell-
derived NS1 induces IL-6 in human PBMCs. Culture medium from transient expression concentrated 
as above was applied to human PBMCs. Treatments are as per panel B, with the inclusion of an extra 
control – medium from CHO cells exposed to PEI transfection reagent (PEI SN). Released IL-6 was 
measured by ELISA and data are the mean ± SD from four donors, except for immunodepleted samples 
which represent 3 donors.  
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Fig. 3. Induction of TNF-α and IL-6 mRNAs in mouse macrophages and human PBMCs in 
response to S2-derived NS1 protein. (A) Dose-dependent production of cytokine mRNAs from 
treated murine BMMs. BMMs were incubated with purified NS1 (1.25, 2.5, 5, 10, 20 and 40 µg/ml) or 
LPS (0.1, 1, 10 and 100 ng/ml) and harvested after 3 hours. Expression of individual mRNAs were 
measured by real time PCR and expressed relative to Hprt mRNA. (B) Time course of BMM response 
to LPS and NS1. BMMs were incubated with either no additions (control), NS1 (40 µg/ml) or LPS (1 
ng/ml) for the indicated times. Cytokine mRNAs were measured as described in panel A. A control 
sample is included for each time point, but generally cannot be seen on this scale. (C) Time course of 
PBMC response to LPS and NS1. PBMCs were treated with no additions (control), NS1 (10µg/ml) or 
LPS (10 ng/ml) for the indicated times. Cytokine mRNAs were measured by real time PCR and 
expressed relative to Hprt mRNA. Data are mean ± range from two independent experiments (A and B) 
or mean ± SD from four donors (C).  
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Fig. 4. NS1 activates cells via TLR4. (A) Down-modulation of BMM cell surface CSF1R by NS1 
requires TLR4. CSF1R on wild-type C57BL/6 BMMs (WT), Tlr4-/- and MyD88-/-/Trif-/- BMMs was 
measured after 1 hour treatment with CSF1 (104 U/ml), LPS (100 ng/ml) and NS1 (10 µg/ml). (B) 
Down-modulation of BMM cell surface CSF1R by NS1 does not require TLR2. BALB/c wild-type 
BMMs (WT) and Tlr2-/- BMMs were treated as in A or with Pam3CSK4 (100 ng/ml) as a TLR2 
stimulus. (C-D) NS1-induction of TNF-α and IL-1β mRNAs requires TLR4. Wild-type (C57BL/6) and 
Tlr4-/- BMMs were incubated with 10 µg/ml NS1, 1 ng/ml LPS or 100 ng/ml Pam3CSK4 for 3 hours, 
and mRNA expression determined using real time PCR relative to Hprt mRNA. (E-F) NS1 induction 
of cytokine mRNAs does not require TLR2. Wild-type BALB/c (WT) and Tlr2-/- BMMs were treated 
as in (C). (G-H) HEK293 cells expressing human TLR4 and MD-2 (G), but not TLR2 (H) respond to 3 
hours treatment with NS1 (10 µg/ml), with induction of IL-8 mRNA, measured by real time PCR 
relative to Hprt mRNA, and normalized to the control sample. LPS (10 ng/ml) and Pam3CSK4 (100 
ng/ml) provide control stimuli for TLR4 and TLR2 respectively. Data are mean ± SD of three 
independent experiments (A), or mean ± range from two independent experiments (B to H). 
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Fig. 5. Co-localization of NS1 and TLR4 on adherent PBMCs. PBMCs were allowed to adhere to 
coverslips for two hours and were then treated with 10 µg/ml NS1 for 45 minutes, prior to fixation. 
Cells were stained for cell surface TLR4 (red) and NS1 (green) without permeablization. (A) 
Orthographic and planar projections were obtained by confocal microscopy. In the right hand panel 
regions of co-localization appear as yellow (selected regions arrowed). Single color controls showed no 
bleed between fluorescence channels. There was no background staining with secondary antibodies 
alone, and the secondary antibodies were demonstrated to be specific for the species of primary 
antibody (Fig. S5). (B) NS1 binding correlates with TLR4 expression in the mixed PBMC population. 
Cells were stained as per panel A. 
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Fig. 6. TLR4 antagonism blocks NS1 activity in vitro and reduces vascular leak in a murine 
DENV infection model. (A) NS1-induced IL-6 production by PBMCs was inhibited by LPS-RS. Cells 
were pre-incubated with LPS-RS (10 µg/ml) for 30 minutes and subsequently stimulated with LPS 
(100 ng/ml), NS1 (10 µg/ml) or Pam3CSK4 (500 ng/ml) for 24 hours. IL-6 was quantified by ELISA. 
(B) Anti-TLR4 antibody reduces the response to NS1. PBMCs were pre-incubated with 2 µg/ml and 10 
µg/ml anti-TLR4 for 1 hour and then stimulated with NS1, LPS or Pam3CSK4 for 24 hours as above. 
IL-6 was quantified by ELISA. Data are mean ± range for two donors (A and B). (C) NS1 induces 
permeability of HMEC-1 monolayers and its action is inhibited by LPS-RS and anti-TLR4 antibody. 
Confluent cells in transwells were pre-treated with or without LPS-RS (100 µg/ml) or anti-TLR4 
antibody (TLR4 Ab) (20 µg/ml) for 1 hour, and then treated with LPS (100 ng/ml) or NS1 (10 µg/ml). 
Monolayer integrity was assessed by measurement of transendothelial electrical resistance (TEER) at 
the indicated times. Data are mean ± SD over four replicate wells. (D and E) AG129 mice were 
injected i.p. with 50 µg LPS-RS or saline, 1 hour prior to infection with DENV2-D220 (104 pfu, i.p.). 
Mice were treated daily with the same doses of LPS-RS or saline. Evans blue was administered i.v. on 
day 4 post infection and allowed to circulate for 2 hours before mice were anaesthetised, perfused, and 
organs harvested. Dye content from intestines (D) and liver (E) was assessed colorimetrically after 
extraction into dimethylformamide to assess relative vascular integrity. Mean ± SD are indicated for 
n=5-7. Statistical significance was assessed by one-way ANOVA (Sidak multiple comparisons test; 
*p<0.05, **p<0.01,  ****p<0.0001). 
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SUPPLEMENTARY MATERIAL            Modhiran et al 
 
Materials and Methods 
 
Cell Culture 
Bone marrow was sourced from Tlr4-/- and MyD88-/-/Trif-/- mice on a C57BL/6 background, Tlr2-/- mice 
on a BALB/c background, C57BL/6 and BALB/c wildtype mice. Human PBMCs were isolated from 
healthy donors by Ficoll-Paque (GE Healthcare Life Sciences) density centrifugation. Mouse 
macrophages, RAW264 reporter cell line and PBMCs were cultured in RPMI-1640 medium 
supplemented with 10% fetal bovine serum, 100 IU/ml penicillin and 100 µg/ml of streptomycin 
(reagents from Life Technologies). CHO suspension cells were grown in CD CHO medium (Life 
Technologies) supplemented with 8 mM glutamine. HEK293 cells stably transfected with hTLR2 or 
hTLR4/MD-2 were grown in DMEM supplemented with 10% FSC and selective antibiotics. HMEC-1 
cells were grown in MCDB 131 medium (Life Technologies) supplemented with 10% FCS, 1 µg/ml of 
hydrocortisone (Sigma-Aldrich) and 10 ng/ml of human epidermal growth factor (Sigma-Aldrich). 
Cells were confirmed as mycoplasma-free. 
 
Generation and purification of DENV-2 NS1 
A stable S2 cell line constitutively expressing recombinant DENV2 NS1 was used for NS1 protein 
production. Cells were maintained in SF900II medium supplemented with 5 µg/ml of blasticidin (Life 
Technologies). The medium was harvested at day 7 or when the cells reached the density of 2x108 
cells/ml. The protein was affinity purified using a 2A5.1 (anti-NS1 monoclonal antibody) immuno-
affinity column (monoclonal antibody was coupled to a HiTrap NHS column, GE Healthcare) 
according to manufacturer’s protocol. Briefly, the medium was collected and centrifuged at 4500g for 
15 minutes at 4°C. The clarified medium was filtered through a 0.22 µm filter (Millipore), buffer 
exchanged twice, and concentrated in column harvest buffer (5 mM EDTA, 100 mM Tris, 150 mM 
NaCl pH 7.4) through a cross-flow system with two 50 kDa cut-off Viva slice cassettes (Sartorius). The 
buffer-exchanged NS1 solution was injected into AKTA FPLC and loaded onto a 2A5.1 immuno-
affinity column that had been pre-equilibrated with 10 volumes of harvest buffer. Following protein 
binding, the column was washed with 5-10 column volumes of elution buffer (5 mM EDTA, 100 mM 
Tris, 150 mM NaCl,  20 mM diethylamine pH 11.5). One ml fractions were collected in 1.5 ml tubes 
containing 80 µl of sterile Tris-HCl pH 6.8 to neutralize the high pH in the elution buffer. NS1-
containing fractions were pooled and concentrated using Amicon ultra-15 (Amicon) concentrator 
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devices with a membrane cut-off of 100 kDa. The solution was then resuspended in phosphate buffered 
saline (PBS) and filtered using a 0.22 µm membrane and stored at -80°C until use. Purified protein 
concentrations were determined using a BCA assay Kit (Pierce) according to the manufacturer’s 
protocol. 
 
NS1 protein was also transiently expressed in Chinese Hamster Ovary cells (CHO) using a pcDNA 
vector containing a codon optimized NS1 sequence (ShineGene). The NS1 expression plasmid and 
empty vector were transfected into CHO cells at a density of 1x106 cells/ml using polyethylenimine 
(PEI) at a 4:1 ratio of PEI to plasmid DNA (DNA at 3µg/ml). After 4 hours of transfection, cells were 
washed with medium 3 times to remove the transfection reagent and DNA.  The medium was harvested 
2 days post-transfection. Media from untransfected cells and from pcDNA3.1(+)-transfected cells were 
used as controls. Media were concentrated approximately 100-fold using disposable 100 kDa cut-off 
spin columns and NS1 levels estimated by capture-ELISA (17), using a purified recombinant NS1 
standard. Both CHO cells and the S2 line were free of mycoplasma. 
 
Immunodepletion of NS1 
Immunodepletions of NS1 were performed using mouse monoclonal anti-NS1 antibody (1H7 or 2A5) 
and control anti-E antibody (3H5), purified from ascites and bound to protein G Dynabeads (Life 
Technologies). Purified NS1 from S2 cells and CHO medium were mixed with beads and incubated for 
2 hours at room temperature. The supernatants were collected following magnet-mediated bead 
separation, as NS1-depleted and control-depleted samples. The efficiency of NS1 depletion was 
confirmed by western blot using rabbit anti-NS1 antibody. 
 
Purification of monoclonal antibodies  
Antibodies in mouse ascites were purified in-house. All steps were performed at 4°C with 0.22 µm 
filtered buffers. The ascites was pre-incubated with 60 mM sodium phosphate pH 7 overnight at 4°C on 
gentle agitation at a 1:2 ratio. The mixture was then centrifuged at 180g for 10 min. The supernatant 
was filtered through a 0.22 µm filter. The clarified solution was then loaded on to a HiTrap protein G 
column (GE Healthcare) using an AKTA FPLC with superloop fitted (GE Healthcare). The column 
was washed with 10 column volumes of 20 mM sodium phosphate pH 7 at a flow rate of 0.5 
ml/minute. Following equilibration the ascites was injected into the column and washed with 10 
column volumes of equilibration buffer. The antibodies were subsequently eluted with 0.1 M glycine-
HCl pH 2.7 into tubes containing 100 µl of 1 M Tris-HCl pH 9 to rapidly neutralize the low pH buffer 
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and the fractions were analysed by SDS-PAGE and western blot. Peak fractions were pooled, filtered 
and concentrated. 
 
NF-κB-driven promoter reporter assay 
The murine macrophage-like cell line RAW264.7, stably transfected with the human ELAM (E-
selectin) promoter (-760 to +0) driving expression of enhanced green fluorescent protein (GFP), has 
been described (56). Cells were seeded at 5x105 cells/well on sterilin 25 well bacteriological plates in 
0.5 ml prior to stimulation with the indicated amounts of LPS or purified NS1. After 6 hours cells were 
harvested by washing with PBS three times and harvested in Dulbecco’s PBS containing 0.02% NaN3. 
GFP expression was analysed by flow cytometry on a BD Accuri 6.  
 
Analysis of mRNA by quantitative real-time reverse transcriptase PCR (qRT-PCR) 
Mouse BMMs (with CSF1), or human PBMCs were seeded at 2x106 and 1x106 cells per well in 6-well 
plates 24 hours prior to stimulation with the indicated amount of NS1 or TLR ligands. HEK293 cells 
and HEK293-TLR cell lines were plated overnight at 1x106 per well in 1 ml medium in a 12-well plate, 
treated on the following day and harvested at 3 hours post-treatment. Total RNAs were prepared with 
RNeasy RNA Mini Kit (Qiagen) and cDNA was generated by reverse transcription of 2 µg of total 
RNA with random hexamer primers using a ThermoScript RT Kit (Invitrogen). qPCR was then carried 
out using specific primers set for mouse TNF-α, IL-1β, IL-6, IL-12, IFN-β and human TNF-α, IFN-γ, 
IFN-β, IL-6, IL-1β, IL-8, IP-10 and MCP-1 with SYBER©green PCR MasterMix (Life Technologies) 
according to manufacturer’s recommendations. Analysis was done by Applied Biosystems ViiATM 7 
Real-time PCR system. Levels of gene expression relative to HPRT reference gene were quantified 
using the ΔCT method (57). Primer sequences are shown in Table S1 and S2. 
 
Indirect immunofluorescence and confocal microscopy 
Human PBMCs were isolated and seeded onto coverslips. After 2 hours of incubation, unbound cells 
were removed by washing twice with complete medium. NS1 (10 µg/ml) was added and incubated for 
45 minutes at 37oC. Cells were washed three times with PBS, fixed with 4% paraformaldehyde in PBS 
for 10 minutes and incubated with PBS containing 0.05% non-fat dry milk and 0.05% Tween-20. The 
cells were then stained with rabbit anti-NS1 polyclonal antibody and mouse anti-TLR4 monoclonal 
antibody (HTA125) in PBS for 1 hour at 37oC. Coverslips were washed three times in PBS with 0.05% 
Tween-20 (PBS-T) and incubated with goat anti-rabbit Alexa Fluor 488-conjugated and goat anti-
mouse Alexa Fluor 555-conjugated secondary antibodies (Life Technologies) for 1 hour at 37oC and 
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washed three times in PBS-T. The cells were examined using ZEISS 510 and 710 META microscopy 
at 100x magnification. The images were analyzed using ImageJ version 10.  
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Supplementary Figures 
 
Fig. S1. Purification and characterization of DENV-2 NS1 from S2 cells. (A) Buffer-exchanged 
supernatant from an S2 cell line constitutively expressing recombinant DENV2 NS1 was loaded onto a 
2A5.1 immuno-affinity column. Following washing, NS1 was eluted from the column and analysed 
using SDS-PAGE under reducing conditions and visualized with Coomassie blue staining. A clear band 
corresponding to monomeric NS1 is indicated with an arrow. (B) Size-exclusion chromatography of 
NS1 eluted from the immuno-affinity column separated a peak fraction eluting with a MW of 
approximately 310 kDa, estimated from elution volume on the basis of prior calibration with molecular 
weight standards. This peak fraction was examined by negative-stain electron microscopy revealing a 
homogeneous preparation of typical hexameric NS1 particles. 
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Fig. S2 Dengue NS1 activates a mouse macrophage NF-κB reporter cell line. (A) NS1 and LPS 
activate NF-κB-dependent transcription in a mouse macrophage cell line expressing GFP under the 
control of the ELAM promoter. Cells were treated with NS1 (5, 10, 20, 40 80, 160, 400 µg/ml) or LPS 
(0.0064, 0.032, 0.16, 0.8, 4, 20, 100 ng/ml). Results show expression of GFP, relative to the mean 
fluorescence index of untreated cells. Concentrations are shown on a molar scale, assuming LPS Mr = 
10 kDa and NS1 Mr = 300 kDa. Data are the mean ± SD from 4 independent experiments. (B) NS1 
immuno-depletion prevents NF-κB-dependent promoter activity. ELAM promoter activity was 
monitored as in B, in response to LPS (100 ng/ml), NS1 (40 µg/ml), NS1 immuno-depleted using anti-
NS1 antibody or isotype-matched control antibody (confirmed in western blot inset). Data show mean 
± SD of 3 independent experiments. 
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Fig. S3. Polymyxin B can efficiently inhibit LPS in the presence of NS1. Purified NS1 (2.5 µg/ml) 
and LPS (10 ng/ml) were added to human PBMCs and IL-6 levels assessed using a capture ELISA. 
NS1 and LPS were either added individually, or premixed and incubated for 1 hour prior to addition. 
Single reagents or NS1-LPS mixture were further treated by the addition of Polymyxin B (PxB - 25 
µg/ml) for 30 minutes prior to addition to cells. Polymyxin B resulted in complete reduction of IL-6 
production in the case of LPS alone, no inhibition for NS1 alone and only partial inhibition for the LPS 
and NS1 combination (equivalent to inhibition of the LPS but not NS1 response). Thus NS1 was not 
able to bind and sequester LPS in a manner that made it inaccessible to polymyxin B. The molar ratio 
of NS1:LPS in the mixed sample was approximately 8:1, assuming LPS Mr = 10 kDa, NS1 Mr = 300 
kDa. Bars show the mean ± range from 2 donors.  
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Fig. S4. NS1 protein causes the loss of surface CSF1R on murine BMMs. Cells were starved of 
CSF1 overnight to up-regulate CSF1R expression. Following treatment with CSF1, LPS or NS1 for 
one hour, the level of surface CSF1R was assessed by antibody staining and flow cytometry. An 
example of primary data for surface CSF1R expression is shown, including CSF1-starved BMMs 
which were unstained, stained, but left untreated (CTL), treated with CSF1 (104 U/ml), LPS (100 
ng/ml) or NS1 (10 µg/ml). 
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Fig. S5. Recombinant NS1 from other flaviviruses have immunostimulatory activity. As per 
Figure 2C, supernatants from CHO cells transfected with plasmids encoding NS1 from West Nile virus 
(WNV-NY99) and yellow fever virus (YFV), along with matched control supernatants or media, were 
concentrated with 100 kDa cut-off filters and applied to human PBMCs for 24 hours. Cells were also 
treated with concentrated medium from untransfected cells (CTL), CHO cells exposed to PEI 
transfection reagent (PEI SN) or cells transfected with empty vector (pcDNA SN). Released IL-6 was 
quantified by capture ELISA and data plotted are the mean ± SE from four donors over 3 independent 
experiments and assessed by one-way ANOVA (Sidak multiple comparisons test; *p<0.05). NS1 
expression was confirmed via western blot (inset) probed with polyclonal rabbit anti-DENV2 NS1, 
which cross-reacts with these other species. 
 
0
500
1000
1500
Un
tre
at
ed CT
L
PE
I S
N
pc
DN
A 
 S
N
YF
V 
NS
1 
SN
 
W
NV
 N
S1
 S
N
IL
-6
 (p
g/
m
l)
* *
	   32	  
 
Fig. S6. Induction of cytokine mRNAs in C57BL/6 BMMs and human PBMCs in response to S2-
derived NS1 protein. (A) Dose-dependent production of cytokine mRNAs from treated murine 
BMMs. BMMs were incubated with purified NS1 (1.25, 2.5, 5, 10, 20 and 40 µg/ml) or LPS (0.1, 1, 10 
and 100 ng/ml) and harvested after 3 hours. Expression of individual mRNAs was measured by real 
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time PCR and expressed relative to mRNA for HPRT. (B) Time course of BMM response to LPS and 
NS1. BMMs were incubated with either no additions (control), NS1 (40 µg/ml) or LPS (1 ng/ml) for 
the indicated times. Cytokine mRNAs were measured as described in panel A. A control sample is 
included for each time point, but generally cannot be seen on this scale. (C) Time course of PBMC 
response to LPS and NS1. PBMCs were treated with no additions (control), NS1 (10 µg/ml) or LPS (10 
ng/ml) for the indicated times. Cytokine mRNAs were measured by real time PCR and expressed 
relative to mRNA for HPRT. Data are mean ± range from two independent experiments (A and B) or 
mean ± SD from four donors (C). 
 
 
 
 
Fig. S7. NS1 activates cells via TLR4. (A) NS1 induction of cytokine mRNAs requires TLR4. Wild-
type C57BL/6 (WT) and Tlr4-/- (TLR4 KO) BMMs were incubated with 10 µg/ml NS1, 1 ng/ml LPS or 
100 ng/ml Pam3CSK4 for 3 hours, and expression of mRNA for IL-6, IL-12 and IFN-β determined 
using real time PCR relative to mRNA for HPRT. (B) NS1-induction of cytokine mRNAs does not 
require TLR2. Wild-type BALB/c (WT) and Tlr2-/- (TLR2 KO) BMMs were treated as in panel A, and 
mRNA expression determined using real time PCR relative to mRNA for HPRT. Data are the mean ± 
range from two experiments. 
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Fig. S8. Controls for co-localization of NS1 and TLR4 on adherent PBMCs. Controls were 
performed with single color staining to ensure lack of bleed through of fluorescence between channels 
(not shown), as well as a single primary antibody with the mismatched secondary antibody to ensure 
specificity of the secondary antibody. PBMCs were allowed to adhere to coverslips for two hours 
before incubation with or without NS1 (10 µg/ml) for 45 minutes. Co-localization of cell surface NS1 
and TLR4 was analysed by immunofluorescence confocal microscopy. NS1 was detected using anti-
NS1 rabbit polyclonal antibody and goat anti-rabbit Alexa Fluor 488-conjugated secondary antibody 
(green). Surface TLR4 was labeled using an anti-TLR4 antibody (HTA125) monoclonal antibody and a 
A
B
C
D
NS1TLR4 OverlayBrightfield
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goat anti-mouse Alexa Fluor 555-conjugated secondary antibody (red). (A) Cells without NS1 were 
stained with mouse anti-TLR4, and anti-rabbit secondary antibody to show lack of staining. (B) Cells 
treated with NS1 were stained with rabbit anti-NS1, and anti-mouse secondary antibody to show lack 
of staining. (C) Cells without NS1, and (D) cells with NS1 were both stained with mouse anti-TLR4, 
and rabbit anti-NS1 together, followed by both secondary antibodies.  
 
 
 
 
 
Fig. S9. Inhibition of PBMC production of IL-8 in response to NS1 by anti-TLR4 antibody and 
TLR4 antagonist. As in Figure 6 A and B, cells were pre-incubated with or without LPS-RS (10 
µg/ml) for 30 minutes or 2 µg/ml and 10 µg/ml anti-TLR4 for 1 hour and then stimulated with LPS 
(100 ng/ml), NS1 (10 µg/ml) or Pam3CSK4 (500 ng/ml) for 24 hours. IL-8 was assessed by capture-
ELISA. Data are mean ± SD for three donors. 
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Table S1. List of mouse primers for RT-PCR 
 
Primer name Sequences (5' to 3') 
IL-6 Forward CAGAATTGCCATCGTACAACTCTTTTCTCA 
IL-6 Reverse AAGTGCATCATCGTTGTTCATACA 
TNF-α Forward CATCTTCTCAAAATTCGAGTGACAA 
TNF-α Reverse TGGCAGTAGACAAGGTACAACCC 
IL-12 p40 Forward GGAAGCACGGCAGCAGAATA 
IL-12 p40 Reverse AACTTGAGGGAGAAGTAGGAATGG 
IL-1β Forward GAAGCTGATGGCCCTAAACA 
IL-1β Reverse AAGCCCTTGCTGTAGTGGTG 
IFN-β Forward CCACAGCCCTCTCCATCAAC 
IFN-β Reverse TAAATCCTCCCTGCAAACCAA 
HPRT Forward GCAGTACAGCCCCAAAATGG  
HPRT Reverse AACAAAGTCTGGCCTGTATCCAA 
 
Table S2. List of human primers for RT-PCR 
 
Primer name Sequences (5' to 3') 
IL-1β Forward CTGATGGCCCTAAACAGATGAAGT 
IL-1β Reverse AGCCCTTGCTGTAGTGGTGGT 
IL-12 p40 Forward GATGCCGTTCACAAGCTCAAGT 
IL-12 p40 Reverse GACCTCCACCTGCCGAGAAT 
IFN-β Forward CAGTCCTGGAAGAAAAACTGGAGA 
IFN-β Reverse TTGGCCTTCAGGTAATGCAGAA 
IL-8 Forward GGAGAAGTTTTTGAAGAGGGCTGA 
IL-8 Reverse TGCTTGAAGTTTCACTGGCATCTT 
IFN-γ Forward GGAGACCATCAAGGAAGACATGA 
IFN-γ Reverse TGGACATTCAAGTCAGTTACCGAA 
IP-10 Forward TGAAAGCAGTTAGCAAGGAAAGGT 
IP-10 Reverse AGCCTCTGTGTGGTCCATCC 
IL-6 Forward CTCAGCCCTGAGAAAGGAGACAT 
IL-6 Reverse TCAGCCATCTTTGGAAGGTTCA 
MCP-1 Forward AAGTGTCCCAAAGAAGCTGTGATCT 
MCP-1 Reverse TGCTTGTCCAGGTGGTCCAT 
HPRT Forward TCAGGCAGTATAATCCAAAGATGGT 
HPRT Reverse AGTCTGGCTTATATCCAACACTTCG 
 
 
Movie S1. TLR4 and NS1 co-localization on PBMCs; video of immunofluorescence confocal 
microscopy Z stack.  
 
 
